⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
CHRS News
Coherus Oncology, Inc. Common Stock
Keros Therapeutics Appoints Charles Newton to its Board of Directors
globenewswire.com
KROS
LYEL
CHRS
Age Related Macular Degeneration Market to Reach $16.2 billion by 2033, Globally, by 2034 at 5% CAGR: Allied Market Research
prnewswire.com
REGN
NVS
ROG
BIIB
CHRS
SNY
APLS
BHC
IONS
Coherus Oncology to Participate in Upcoming Investor Conferences
globenewswire.com
CHRS
Coherus Oncology, Inc. Announces Closing of Public Offering of Common Stock
globenewswire.com
CHRS
IPSC-derived NK Cells Clinical Trial Pipeline Gains Momentum: 12+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight
globenewswire.com
FATE
INDP
AMGN
NKTR
IBIO
TAK
SNY
INMB
CLMT
VERX
GTBP
BHVN
CHRS
GSK
BMY
MRK
ABBV
AZN
GILD
LLY
KYMR
REGN
SPRY
Coherus Oncology, Inc. Announces Pricing of Public Offering of Common Stock
globenewswire.com
CHRS
Coherus Oncology, Inc. Announces Proposed Public Offering of Common Stock
globenewswire.com
CHRS
TIGIT Inhibitors Market Poised for Strong Growth Through 2034, Driven by Expanding Immuno-Oncology Pipeline | DelveInsight
prnewswire.com
RCUS
GILD
AZN
CGEN
CHRS
Registration-Ready: How 2026's Clinical Leaders Are Beating Cancer Benchmarks
prnewswire.com
ONCY
CHRS
MRNA
VIR
MRK
Functional Force: Precision Platforms Disrupt the 2026 Tumor Landscape
prnewswire.com
GTBP
IBRX
ERAS
CHRS
NBP